Quantcast

Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
October 22, 2014, 06:48:28 PM

Login with username, password and session length


Members
Stats
  • Total Posts: 643114
  • Total Topics: 48933
  • Online Today: 228
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: CTLA Ipilimumab human antibdy role regulating natural immune responses.  (Read 1105 times)

0 Members and 1 Guest are viewing this topic.

Offline bimazek

  • Member
  • Posts: 781
this is a great step forward for immunotherapy, and for
patients with melanoma cancer.  It may or may not have application to hiv in future, that must be studied but there is some hope because the antigen profile is similar to pd-1

pd-1 and ctla are related but different, like the control knobs in a jet cockpit they do different things and are receptors on many but different sets of cells, this is good news in many ways.  this company is working with harvard on hiv and many other diseases.

ctla was discovered before
pd-1

http://www.medarex.com/cgi-local/item.pl/20070605-1011294

Ipilimumab is a fully human antibody that binds to CTLA-4 (cytotoxic T
lymphocyte-associated antigen 4), a molecule on T-cells that is believed to play a
critical role in regulating natural immune responses.  The absence or presence of
CTLA-4 can augment or suppress the immune system's T-cell response in fighting
disease.  Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining
an active immune response in its attack on cancer cells. June 5 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) and   Bristol-Myers Squibb Company (NYSE: BMY) today presented results from multiple
clinical studies of ipilimumab (MDX-010), an investigational immunotherapy, for
patients with advanced melanoma.  The results demonstrated an anti-tumor response in
some patients with advanced melanoma either as a monotherapy or in combination with
other therapies.  The results of the monotherapy study showed that 19% of patients
(17/88) with advanced melanoma treated with ipilimumab experienced control of their
disease, including tumor shrinkage and stabilization.

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.